Cadila Pharma is one of the top Active Pharmaceuticals Ingredient (API) manufacturing companies in the world, and one of the few pharmaceutical companies that is vertically-integrated with a very strong and independent positioning in both the API market.
Spanning over 80,000 square meters, our API manufacturing facility is globally certified by the US FDA, ISO 9001:2008, COFEPRIS, PMDA Japan, EDQM Europe, TGA Australia, and WHO Geneva. Our focus on cost competitiveness and quality has been a key driver of our profitability and growth in the formulations market as well.
Our diversified portfolio of APIs caters to over 90 countries. At present, we offer over 38 APIs and intermediates across various therapeutic categories - respiratory, diabetology, gastroenterology, pain management (antimigraine), orthopedics and many more.
We synthesise high-quality API solutions for leading therapy areas. We remain customer-focused in all our approaches and strive to provide end-to-end support throughout the production process. Our combined capabilities in Process Chemistry, Analytical Development, Regulatory Affairs, Intellectual Property, and Process Scale-up ensure seamless project management and fulfilment.
across various therapeutic categories-respiratory, diabetology, gastroenterology, pain management & orthopaedics.
with a significant presence in regulated markets, viz. USA, Europe, and Japan.
Unmatched API portfolio with certificates of sustainability, and many more in the pipeline.
We excel at producing high-quality Active Pharmaceutical Ingredients (APIs) through cost-effective, environmentally friendly synthesis. We provide comprehensive support to clients, from gram to kilo quantities, along with regulatory assistance.
Ankleshwar, Gujarat
We operate two advanced manufacturing facilities (Unit 1 & Unit 2), approved by USFDA and EU-GMP, delivering:
Flexible, compliant, and scalable CDMO solutions
Global quality standards trusted by innovators and generic partners
Robust infrastructure enabling seamless technology transfer and reliable commercial supply
Our in-house cGMP-compliant Pilot Plant and a centralised Analytical Research Laboratory, conforming to international standards. Our novel laboratory, the Process Engineering Research Lab (PERL), is for research, innovation, and optimisation of API manufacturing process engineering.
Accredited by
Accredited by
Dahej, Gujarat
Our state-of-the-art API manufacturing plant, the Greenfield API Facility (DCS-Controlled), is equipped with a Distributed Control System (DCS). This facility is designed to:
Produce APIs with high purity and consistency
Ensure greater precision, process efficiency, and safety
Reduce environmental impact through sustainable operations
Provide the capacity and scalability to meet increasing global customer demand
The DCS technology used in the plant ensures high levels of purity and consistency and helps reduce its environmental impact. The plant has a manufacturing capacity of up to 150 metric tons per year to provide high-quality, cost-effective API.
Disclaimer: This list of products and reference to any product therein should not be construed and/or constituted transaction where it is not permitted under Patent law of the country and/or is not authorized by other laws and regulations of the country.
| Sr. No. | Therapeutic category | Products |
|---|---|---|
| 1 | Anti-Gout | Febuxostat |
| 2 | Anti-Hypertensive | Labetalol |
| 3 | Anti-Hypertensive | Sacubitril Sodium |
| 4 | Anti-Hypertensive | Sacubitril Valsartan |
| 5 | Anti-migraine Agent | Sumitriptan |
| 6 | Anti-migraine Agent | Rizatriptan |
| 7 | Anti-Psychotic | Paroxetine HCl Hemihydrate |
| 8 | Anti-Psychotic | Donepezil HCI |
| 9 | Histamne H2-Receptor Blocker Antagonists/H-2 Blockers | Famotidine |
| 10 | Potassium-Competitive Acid Blockers (PCABs) | Vonoprazan Fumarate |
| 11 | Potassium-Competitive Acid Blockers (PCABs) | Tegoprazan |
Disclaimer: This list of products and reference to any product therein should not be construed and/or constituted transaction where it is not permitted under Patent law of the country and/or is not authorized by other laws and regulations of the country.
Contact Us
Our Story
Businesses
Therapies
Corporate Identification No : U24231GJ1991PLC015132
©2026 Cadila Pharmaceuticals. All rights reserved
